Drug updated on 5/17/2024
Dosage Form | Tablet (oral; 25 mg, 100 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Latest News
Summary
- Lorlatinib (Lorbrena) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
- Nine studies were reviewed to compare the safety and efficacy of lorlatinib to other ALK inhibitors in treating NSCLC.
- In terms of progression-free survival, lorlatinib shows superior results compared to crizotinib and closely follows alectinib and brigatinib; it also demonstrates remarkable benefits in controlling CNS progression among populations with baseline brain metastases.
- While comparisons involving overall survival improvements remain less conclusive for lorlatinib, alectinib has been shown to significantly improve OS compared to other ALK inhibitors like crizotinib.
- Adverse events associated with lorlatinib are noted as being among the highest when compared to other ALK inhibitors, including changes in lipid levels, weight gain, cognitive effects, and mood effects; however, its high efficacy, particularly in managing CNS involvement, distinguishes it from others.
- Alectinib emerges frequently as a preferred option due its balance between efficacy and safety, especially within the first-line or second-line settings, while brigatinib exhibits significant improvement in patient-reported outcomes.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Lorbrena (lorlatinib) Prescribing Information. | 2023 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
A pragmatic guide for management of adverse events associated with lorlatinib. | 2024 | Lung Cancer |
Regimen Reference Order – THOR – lorlatinib. | 2023 | Cancer Care Manitoba |
Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO living guideline. | 2022 | Journal of Clinical Oncology |
Non–small cell lung cancer, version 3.2022. | 2022 | Journal of the National Comprehensive Cancer Network |
Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. | 2020 | Advances in Therapy |
The Japanese Lung Cancer Society guideline for non-small cell lung cancer, stage IV. | 2019 | International Journal of Clinical Oncology |